证券日报网讯 1月9日，立方制药发布公告称，近日，公司全资子公司合肥诚志生物制药有限公司收到 国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。 （文章来源：证券日报） ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

格隆汇1月9日丨立方制药(003020.SZ)公布，全资子公司合肥诚志生物制药有限公司（简称"诚志生物"） 收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠是一种苯丙酸 类非甾体抗炎药，具有较好的镇痛、消炎、解热作用，尤其是镇痛作用较强。其适应症为：①类风湿关 节炎、骨性关节炎、腰痛症、肩关节周围炎、颈肩腕综合征、牙痛的消炎和镇痛；②手术后，外伤后及 拔牙后的镇痛和消炎；③急性上呼吸道炎（包括伴有急性支气管炎的急性上呼吸道炎）的解热和镇痛。 本品原研为日本日医工株式会社。截至本公告日，本品国内暂无进口产品获批上市，国内企业除诚志生 物外，另有7家企业持有该产品药品批文。 ...

立方制药（003020）(003020.SZ)公告，公司全资子公司合肥诚志生物制药有限公司("诚志生物")收到国 家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠是一种苯丙酸类非甾 体抗炎药，具有较好的镇痛、消炎、解热作用，尤其是镇痛作用较强。 ...

智通财经APP讯，立方制药(003020.SZ)公告，公司全资子公司合肥诚志生物制药有限公司("诚志生物") 收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠是一种苯丙酸 类非甾体抗炎药，具有较好的镇痛、消炎、解热作用，尤其是镇痛作用较强。 ...

(本文来自第一财经) 立方制药公告，全资子公司诚志生物收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注 册证书》。该药品是一种苯丙酸类非甾体抗炎药，具有较好的镇痛、消炎、解热作用。截至公告日，国 内暂无进口产品获批上市，诚志生物成为国内第8家持有该产品药品批文的企业。该证书的取得将进一 步丰富立方制药的产品管线，提升市场竞争力，但药品生产和销售仍受政策和市场等因素影响，存在不 确定性。 ...

立方制药1月9日公告，全资子公司诚志生物收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液 《药品注册证书》。该药品是一种苯丙酸类非甾体抗炎药，具有较好的镇痛、消炎、解热作用。截至公 告日，国内暂无进口产品获批上市，诚志生物成为国内第8家持有该产品药品批文的企业。该证书的取 得将进一步丰富立方制药的产品管线，提升市场竞争力，但药品生产和销售仍受政策和市场等因素影 响，存在不确定性。 ...

立方制药(003020.SZ)公告称，全资子公司诚志生物收到国家药品监督管理局核准签发的洛索洛芬钠口 服溶液《药品注册证书》。该药品是一种苯丙酸类非甾体抗炎药，具有较好的镇痛、消炎、解热作用。 截至公告日，国内暂无进口产品获批上市，诚志生物成为国内第8家持有该产品药品批文的企业。该证 书的取得将进一步丰富立方制药的产品管线，提升市场竞争力，但药品生产和销售仍受政策和市场等因 素影响，存在不确定性。 ...

人民财讯1月9日电，立方制药（003020）1月9日公告，近日，公司全资子公司诚志生物收到国家药品监 督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠是一种苯丙酸类非甾体抗炎 药，具有较好的镇痛、消炎、解热作用，尤其是镇痛作用较强。 ...

Group 1 - The company, Jiutian Pharmaceutical, has responded to investor inquiries regarding its products for treating joint pain, which include Loxoprofen Sodium Gel Patches, Ketoprofen Gel Patches, Anti-inflammatory Pain Relief Plasters, and Ketoprofen Gel [1] - The company also offers antipyretic medications such as Loxoprofen Sodium Tablets and Loxoprofen Sodium Oral Solutions [1]